logo

For the Inventor, By the Inventor

Boothwyn, PA, United States of America

Lihua Chen

This inventor holds 11 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Incyte Corporation, Bristol-Myers Squibb Compnay, Bristol-Myers Squibb Pharma Company. Active years: 2002-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lihua Chen. Retrieved from https://idiyas.com/inventor/lihua-chen-nhr0xytw

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 11

% Patents Active = 100.0



Average Co-Inventor Count = 6.9

ph-index = 4

Forward Citations = 42(Granted Patents)


Location History:

  • Wilmington, DE (US) (2002 - 2006)
  • Boothwyn, PA (US) (2006 - 2015)

Company Filing History:

goldMedal5 out of 687 
 
Incyte Corporation
 patents
silverMedal3 out of 3,745 
 
Bristol-Myers Squibb Compnay
 patents
bronzeMedal3 out of 234 
 
Bristol-Myers Squibb Pharma Company
 patents

Years Active: 2002-2015

Loading Chart...
Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents
1. 9067921 - Piperazinylpiperidine derivatives as chemokine receptor antagonists (2015-06-30),
2. 8680104 - Piperazinylpiperidine derivatives as chemokine receptor antagonists (2014-03-25),
3. 8268826 - Piperazinylpiperidine derivatives as chemokine receptor antagonists (2012-09-18),
4. 7998959 - Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same (2011-08-16),
5. 7678798 - Piperazinylpiperidine derivatives as chemokine receptor antagonists (2010-03-16),
6. 7595317 - Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases (2009-09-29),
7. 7294624 - Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases (2007-11-13),
8. 7132432 - Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) (2006-11-07),
9. 6984648 - Cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α (2006-01-10),
10. 6743807 - Cyclic &bgr;-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-&agr; (2004-06-01),
11. 6455522 - Cyclic sulfonamide derivatives as metalloproteinase inhibitors (2002-09-24),

Title: Lihua Chen: Innovator in Chemokine Receptor Antagonists

Introduction

Lihua Chen is a prominent inventor based in Boothwyn, PA (US). He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target chemokine receptors. With a total of 11 patents to his name, Chen's work has the potential to impact the treatment of various diseases.

Latest Patents

One of Chen's latest patents involves piperazinylpiperidine derivatives as chemokine receptor antagonists. This invention relates to compounds that modulate the activity of or bind to chemokine receptors such as CCR5. The compounds are designed to be selective for CCR5 and can be utilized in treating diseases associated with chemokine receptor expression or activity, including inflammatory diseases, immune diseases, and viral infections.

Career Highlights

Throughout his career, Lihua Chen has worked with notable companies in the pharmaceutical industry, including Incyte Corporation and Bristol-Myers Squibb Pharma Company. His experience in these organizations has allowed him to advance his research and contribute to the development of innovative therapeutic solutions.

Collaborations

Chen has collaborated with several professionals in his field, including Chu-Biao Xue and Jingwu Duan. These collaborations have fostered a productive environment for research and innovation.

Conclusion

Lihua Chen's contributions to the field of chemokine receptor antagonists highlight his role as a key innovator in medicinal chemistry. His work continues to pave the way for advancements in the treatment of various diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…